Targeting tumor stem cells
Clinical trial at the University of Cincinnati involves targeting stem cells for personalized treatment of brain cancer
Researchers at the University of Cincinnati are leading the local arm of a study looking at ways to test for chemosensitivity in brain tumor stem cells to determine treatment response and outcomes for patients.
The primary site for the clinical trial is Marshall University in West Virginia, but Nicholas Marko, MD, director of the UC Brain Tumor Center, is leading the study locally.
“We are collecting tumor tissue from our patients and sending it to our collaborators at Marshall,” says Marko, who is also an associate professor of neurosurgery at the UC College of Medicine and a member of both the Gardner Neuroscience and Cancer Institutes. “These researchers grow stem cells from the tumor and then try to kill those cells with a number of chemotherapy drugs. The therapy that works best, based on these outcomes, is the patient’s designated study drug.”
Marko says when glioblastoma, an extremely malignant form of brain tumor, recurs in patients, the treatment options are often minimal, as surgery and radiation are not usually a possibility.
“In this study, patients with recurrent glioblastoma will receive standard therapy, including surgery if the tumor can be removed, and for the chemotherapy portion of their treatment, participants will be randomized between treatments chosen by the physician—standard cancer treatments—or the personally-selected, chemosensitivity drug. The goal is to see if this personalized therapy is more effective than standard of care.
“The idea is similar to when we test for bacterial sensitivity against antibiotics, in case of a bacterial infection. The test, in this case, uses sample specimens obtained following surgery for the treatment of brain cancer.”
Marko says that participants will be assessed by either brain MRI with contrast or CT scans at two to three month intervals after therapies are administered.
“The hope is that this study will lead to more personalized, targeted treatment for patients with a very serious cancer,” he says.
This study is being funded by ChemoID. Marko cites no conflict of interest.
*Photo credit: Colleen Kelley / University of Cincinnati, Communication Services
To find out more about enrolling in the study, call 513-418-2282.
Related Stories
When grief doesn't end: Nursing PhD students bring a classroom theory to Ohio families
October 29, 2026
Most of us think of grief as something with an ending. A loss happens, it hurts, and over time the hurt fades. For many parents of children with developmental disabilities, it doesn't work that way. The sadness can quiet down for months or years and then come back. It might return on the first day of kindergarten, at a cousin's wedding, at a high school graduation, or on the day a young adult ages out of school services. Nurses and researchers have a name for this: chronic sorrow. Last October, two University of Cincinnati College of Nursing PhD students helped bring that name to a room of families, people with disabilities and the professionals who support them.
UC engineers drones that know if they're damaged
October 29, 2026
UC engineering students are developing drones that can work in warehouses using a digital twin and others that can warn of damaged propellers or motors before a flight.
UC student's NFL internship leads to $20,000 gift to reduce loan burden
October 29, 2026
University of Cincinnati athletic training graduate student Savannah Posey interned with the Buffalo Bills during training camp and received a surprise $20,000 gift toward her student loans from safety C.J. Gardner-Johnson through his Ceedy Cares Foundation.